Program in Pharmacoepidemiology

Publications

  1. Diabetic Retinopathy Risk in SGLT2i vs GLP1RA Initiators With CKD Stages 3-4 and Type 2 Diabetes - PubMed Kidney Med. 2026.
  2. Comparative Renal Effectiveness of GLP-1RA and SGLT2i in US Veterans with Type 2 Diabetes and CKD - PubMed Clin J Am Soc Nephrol. 2026.
  3. Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study - PubMed Diabetes Care. 2026. 
  4. Safety of Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes and CKD - PubMed Am J Kidney Dis. 2026.
  5. Enhancing Evidence Generation by Linking Randomized Clinical Trials to Real-World Data: The INVESTED-Medicare Linkage Study - PubMed Clin Pharmacol Ther. 2026.
  6. Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study - PubMed Cardiovasc Diabetol. 2026.
  7. An Observational Study of Post-hip Fracture Outcomes in Older Adults with Type 2 Diabetes - PubMed J Gen Intern Med. 2026.
  8. Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study - PubMed Diabetes Obes Metab. 2026.
  9. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations - PubMed Diabetes Care. 2026.
  10. Diabetic Ketoacidosis Risk in Sodium-Glucose Cotransporter 2 Inhibitors versus Glucagon-Like Peptide-1 Receptor Agonists Initiators with CKD Stages 3-4 and Type 2 Diabetes - PubMed Kidney360. 2026.
  11. Comparative Effectiveness of Current Glucose-lowering Medications in Type 2 Diabetes Mellitus: Emulation of a Modified GRADE Trial - PubMed J Gen Intern Med. 2026.
  12. Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes - PubMed Ann Intern Med. 2026.
  13. Comparative healthcare resource utilization and costs of empagliflozin and GLP-1 receptor agonists in type 2 diabetes - PubMed Diabetes Obes Metab. 2026.
  14. GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population-based study - PubMed Diabetes Obes Metab. 2026. 
  15. Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes - PubMed Diabetes Care. 2025.
  16. Machine learning for predicting cardiovascular events in older adults with type 2 diabetes using Medicare claims and electronic health records - PubMed J Clin Epidemiol. 2025.
  17. Overall uptake and racial, ethnic, and socioeconomic disparities in the use of continuous glucose monitoring devices among insulin-treated older adults with type 2 diabetes Diabetes Care. 2025.
  18. Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study Diabetes Obes Metab. 2025.
  19. Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications among Patients with Chronic Kidney Disease with and without Type 2 Diabetes  Kidney Med. 2025.
  20. Trends in Utilization of Glucose- and Weight-Lowering Medications after Tirzepatide Approval in the United States: A Population-Based Cohort Study Ann Intern Med. 2025.
  21. Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients with Type 2 Diabetes JAMA Intern Med. 2025.
  22. Comparative Effectiveness of Individual Sodium-Glucose Cotransporter 2 Inhibitors                             JAMA Intern Med. 2025.
  23. Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes                                             JAMA Ophthalmol. 2024.
  24. Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study BMJ. 2024.
  25. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study​ BMJ. 2024.
  26. Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes Diabetes Care. 2024.
  27. Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study J Gen Intern Med. 2024.
  28. ​Effectiveness and safety of empagliflozin: final results from the EMPRISE study                                  Diabetologia. 2024.
  29. Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study Cardiovasc Diabetol. 2024.
  30. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients with Type 2 Diabetes JAMA Intern Med. 2024.
  31. High-Dose vs. Standard-Dose Influenza Vaccine and Cardiopulmonary Hospitalization or Mortality: Emulating the INVESTED Trial Using Insurance Claims Data Clin Pharmacol Ther. 2024.
  32. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes Kidney Int. 2023.
  33. Risk of severe hypoglycemia with newer second-line glucose-lowering medications in older adults with type 2 diabetes stratified by known indicators of hypoglycemia risk J Gerontol A Biol Sci Med Sci. 2023.
  34. Achieving comparability in glycemic control between antidiabetic treatment strategies in pregnancy when using real world data Pharmacoepidemiol Drug Saf. 2023.
  35. Successful implementation of a stakeholder engagement program for pharmacoepidemiologic research Pharmacoepidemiol Drug Saf. 2023.
  36. ​Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes  Diabetes Care. 2023.
  37. Stratified analysis in comparative effectiveness studies that emulate randomized trials​ Pharmacoepidemiol Drug Saf. 2023.
  38. Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom Diabetes Obes Metab. 2023.
  39. Antidiabetes medication initiation trends in US adults with cirrhosis and type 2 diabetes: A nationwide study​ Diabetes Obes Metab. 2023.
  40. Safety of SGLT2i with regard to bone and mineral metabolism in patients with CKD                                       Curr Opin Nephrol Hypertens. 2023.
  41. Continuous Glucose Monitoring in Adults with Diabetes in Clinical Practice: Increased Access and Education Needed J Gen Intern Med. 2023.
  42. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels JAMA Intern Med. 2023.
  43. Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study Clin J Am Soc Nephrol. 2023.
  44. Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure Diabetes Care. 2023​.
  45. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Ann Intern Med. 2022.
  46. The use of glucose-lowering medications for the treatment of type 2 diabetes mellitus during pregnancy in the United States Endocrinol Diabetes Metab. 2022.
  47. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study Diabetes Obes Metab. 2022.
  48. Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes  Pharmacoepidemiol Drug Saf. 2022​.
  49. Prevalence of Avoidable and Bias-Inflicting Methodological Pitfalls in Real-World Studies of Medication Safety and Effectiveness Clin Pharmacol Ther. 2022.
  50. Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes Clin Gastroenterol Hepatol. 2022.
  51. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes                             Am J Kidney Dis. 2022.
  52. Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data Pharmacoepidemiol Drug Saf. 2022.
  53. Medication Optimization for New Initiators of Empagliflozin for Diabetic Kidney Disease                                 Clin Diabetes. 2022.
  54. Risk of Hospitalization for Heart Failure in Patients With Hyperkalemia Treated With Sodium Zirconium Cyclosilicate Versus Patiromer J Card Fail. 2022.
  55. Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries Diabetes Care. 2022.
  56. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study Ann Intern Med. 2022​.
  57. Evolving channeling in prescribing SGLT-2 inhibitors as first-line treatment for type 2 diabetes Pharmacoepidemiol Drug Saf. 2022.
  58. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes JAMA Netw Open. 2021.
  59. Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study Diabetes Care. 2021.
  60. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease  Ann Intern Med. 2021.
  61. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults Diabetes Care. 2021.
  62. Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments                          Endocr Rev. 2021.
  63. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy Circulation. 2021.
  64. Validation of obesity-related diagnosis codes in claims data                                                                                Diabetes Obes Metab.​ 2021.
  65. The modifying effects of adiposity on the cardiovascular safety of sulphonylureas                                            Diabetes Obes Metab. 2021.
  66. Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States Diabetes Obes Metab.​ 2021.
  67. How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools BMJ Open. 2021.
  68. Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA  Diabetes Care. 2021.
  69. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy Circulation. 2021.
  70. A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes Endocrinol Diabetes Metab.​ 2021.
  71. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease   Ann Intern Med.​ 2021.
  72. Comparative effectiveness of empagliflozin in reducing total cardiovascular events in the empagliflozin comparative effectiveness and safety (EMPRISE) study Journal of the American College of Cardiology. 2021.
  73. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease Clin J Am Soc Nephrol​. 2020.
  74. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study Ann Intern Med. 2020.
  75. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018 Diabetes Care. 2020.
  76. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis Cardiovascular Diabetology. 2020.
  77. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea  JAMA Dermatol. 2020.
  78. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study  BMJ. 2020.
  79. Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications Value Health. 2020.
  80. Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes  Diabetes Obes Metab. 2020.
  81. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care Endocrinol Diabetes Metab. 2019.
  82. Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data  Diabetes Obes Metab. 2019.
  83. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study Ann Intern Med. 2019.
  84. Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing Clin Kidney J. 2019.
  85. Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care Diabetes Obes Metab. 2019.
  86. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care                                          Circulation.​ 2019.
  87. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study                                                                     Ann Intern Med. 2019.
  88. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors Diabetes Obes Metab. 2019.